{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:02:27Z","timestamp":1773097347964,"version":"3.50.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Anti-melanoma differentiation-associated gene 5 (MDA5) antibody is associated with clinically amyopathic dermatomyositis (CADM) with rapidly progressive interstitial lung disease (RP-ILD). Recently, several studies have reported that tofacitinib (TOF), a Janus kinase inhibitor, might be effective for cases of new or refractory RP-ILD in anti-MDA5 antibody-positive CADM; however, it is unknown whether TOF can also be effective for relapsed cases. We herein report a relapsed case of RP-ILD in anti-MDA5 antibody-positive CADM, which was successfully treated by combination therapy with TOF (5\u2009mg twice daily). Our case suggests that TOF may also be a potential treatment option for relapsed cases of this disease.<\/jats:p>","DOI":"10.1093\/mrcr\/rxac049","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T04:00:52Z","timestamp":1654833652000},"page":"92-95","source":"Crossref","is-referenced-by-count":9,"title":["Successful treatment with tofacitinib for relapse of rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis"],"prefix":"10.1093","volume":"7","author":[{"given":"Satoshi","family":"Hama","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5075-8977","authenticated-orcid":false,"given":"Mitsuhiro","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center , Tokyo, Japan"},{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misako","family":"Higashida-Konishi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiro","family":"Oshige","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Takei","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center , Tokyo, Japan"},{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Izumi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center , Tokyo, Japan"},{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisaji","family":"Oshima","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Okano","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"2023010315513960900_R1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrrheum.2016.120","article-title":"Inflammatory myopathies: choosing the right biomarkers to predict ILD in myositis","volume":"12","author":"Gono","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2023010315513960900_R2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaad.2017.12.010","article-title":"Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features","volume":"78","author":"Kurtzman","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023010315513960900_R3","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2169\/internalmedicine.8579-21","article-title":"Dermatomyositis which was double positive for anti-MDA5 and anti-ARS antibodies that was successfully treated by intensive immunosuppressive therapy","volume":"61","author":"Hama","year":"2022","journal-title":"Intern Med"},{"key":"2023010315513960900_R4","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","article-title":"The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM","volume":"51","author":"Koga","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2023010315513960900_R5","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","article-title":"Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients","volume":"57","author":"Sato","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2023010315513960900_R6","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00296-017-3729-y","article-title":"Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody","volume":"37","author":"Isoda","year":"2017","journal-title":"Rheumatol Int"},{"key":"2023010315513960900_R7","first-page":"1719","article-title":"Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute\/subacute interstitial pneumonia in patients with dermatomyositis","volume":"32","author":"Kameda","year":"2005","journal-title":"J Rheumatol"},{"key":"2023010315513960900_R8","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2023010315513960900_R9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"2023010315513960900_R10","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2023010315513960900_R11","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021943","article-title":"Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: a case report","volume":"99","author":"Ishikawa","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2023010315513960900_R12","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023010315513960900_R13","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023010315513960900_R14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2023010315513960900_R15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/14397595.2014.900843","article-title":"Serum interferon-\u03b1 is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis","volume":"25","author":"Horai","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2023010315513960900_R16","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1365-2133.2012.11145.x","article-title":"Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease","volume":"167","author":"Sun","year":"2012","journal-title":"Br J Dermatol"},{"key":"2023010315513960900_R17","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/bjd.16917","article-title":"Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis","volume":"180","author":"Zhang","year":"2019","journal-title":"Br J Dermatol"},{"key":"2023010315513960900_R18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.rmed.2018.06.012","article-title":"Role of IL-15 in interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibody","volume":"141","author":"Takada","year":"2018","journal-title":"Respir Med"},{"key":"2023010315513960900_R19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/joim.13154","article-title":"IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis\/dermatomyositis","volume":"289","author":"Shimizu","year":"2021","journal-title":"J Intern Med"},{"key":"2023010315513960900_R20","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/rheumatology\/kez357","article-title":"Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy","volume":"59","author":"Abe","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2023010315513960900_R21","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2023010315513960900_R22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/jca.21824","article-title":"Therapeutic plasma exchange for clinically amyopathic dermatomyositis (CADM) associated with rapidly progressive interstitial pneumonia","volume":"35","author":"Yamagata","year":"2020","journal-title":"J Clin Apher"},{"key":"2023010315513960900_R23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/jca.21833","article-title":"Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: a case series","volume":"36","author":"Saito","year":"2021","journal-title":"J Clin Apher"},{"key":"2023010315513960900_R24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/24725625.2020.1826641","article-title":"Early initiation of plasma exchange therapy for a patient with anti-MDA5autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease","volume":"5","author":"Sasaki","year":"2021","journal-title":"Mod Rheumatol Case Rep"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxac049\/44167384\/rxac049.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/7\/1\/92\/48482159\/rxac049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/7\/1\/92\/48482159\/rxac049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T15:53:39Z","timestamp":1672761219000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/7\/1\/92\/6605055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,6,10]]},"published-print":{"date-parts":[[2023,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxac049","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,6,10]]}}}